Search - tctmd.com

Displaying 221 - 240 of 256

Sort: Relevancy | Date

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Conference News ESC 2015

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Yael L. Maxwell

August 30, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Daily News

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

February 08, 2015

News Daily News

Hybrid Revascularization a Promising Option for Diabetic Patients

L.A. McKeown

July 24, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

L.A. McKeown

October 15, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

Advertisement

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

Hybrid Revascularization a Promising Option for Diabetic Patients

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content